Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Pharmos(PARS) -- Ignore unavailable to you. Want to Upgrade?

To: Ariella who wrote (880)	6/3/1998 9:35:00 PM
From: Zvi Steinberg	Respond to of 1491

Another outstanding post from Dr. Doug Cappiello, Ophthamologist (yahoo PARS thread): Just wanted you all to know, that on my desk right now are 24 bottles of Lotemax and 12 bottles of Alrex I received as professional samples today. I am especially interested to see the clinical effectiveness of Alrex on the allergy patients. I will also be evaluating the effectiveness of Lotemax on postop patients as well as iritis patients with IOP issues. More important I am told that BOL has selected a partner to market Alrex to the non-Ophthalmology community. They will be speaking with Allergists and Primary Care phyisicians. The announcement should come out in a few weeks. Most interesting, the article about HU-211 acting as an all-purpose neuroprotectant got me thinking. The current rage in glaucoma management focuses on the use of neuroprotectants to prevent deterioration of the optic nerve. Current glaucoma management focuses on drugs to decrease the IOP, because that is the only variable we are able to influence right now. However, it is well known that glaucoma patients often continue to lose vision in spite of excellent IOP control. For this reason, it is felt that a neuroprotectant drug can be very effective in reducing blindness from glaucoma, when coupled with a drug to reduce the IOP. Then it hit me-- if HU-211 can be found to reduce neuronal loss in the optic nerve, it can serve this function as well as all the others we have been speaking of. Since about 2% of the population suffer from glaucoma, the size of this market can be enormous!! Look at thie excerpt I found from a recent meeting in New York on this topic. Is it a coincidence that the scientist quoted in the article comes from Israel? *************************************************************** The Fourth Annual Scientific Think Tank on Optic Nerve Rescue and Restoration was held June 6 and 7, 1997 at the Hotel InterContinental in New York City, New York. Over 40 leading international scientists in glaucoma, immunology, neurology and cell biology gathered to discuss current models of optic nerve damage, brainstorm potential clinical trials for neuroprotectants, and present to their peers the most current ongoing research in the field. Michal Schwartz, Ph.D., of the Weizmann Institute of Science in Rehovot, Israel, said that she was impressed to see for the first time the in-depth discussions that took place between clinicians and scientists. She stated that this meeting was exciting because it became clear that the future of glaucoma is in neuroprotection. ********************************************************************** I wonder if PARS is doing any work in the area of glaucoma. It should be relatively easy to set up an animal model in which glaucoma is produced and animals are treated with topical HU-211 or placebo. Then the animals can be sacrificed and histologic study of the optic nerve can be done to look for differences in glaucomatous damage. Anyone know if this is being done? Anyone from PARS listening?? This can be a huge indication for the drug. Of course all of this is IMHO. Doug